| 词条 | Lifastuzumab vedotin |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = zu/o | target = phosphate-sodium cotransporter | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 1401812-88-1 | ATC_prefix = none | ATC_suffix = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 7IUT83FK6S | KEGG = D11238 | PubChem = | DrugBank = | C=6504 | H=10028 | N=1744 | O=2018 | S=46 | molecular_weight = 151.7 kg/mol | ChemSpiderID = none | synonyms = DNIB0600A }}Lifastuzumab vedotin (DNIB0600A) (INN[1]) is a monoclonal antibody designed for the treatment of cancer.[2] This drug was developed by Genentech/Roche. References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110 | journal = WHO Drug Information | volume = 27 | issue = 4 | year = 2013 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL111.pdf | format=PDF}} {{monoclonal-antibody-stub}}{{monoclonals for tumors}}2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association. 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。